In May 2020, this treatment had obtained authorization to be tested against the coronavirus during a clinical trial comprising 1,034 patients.

But on Friday, the French biotech Abivax announced to end it because of its "lack of efficiency". 

The French biotech Abivax announced to end the clinical trial of its drug candidate against Covid-19, due to its "lack of effectiveness", in a press release Friday evening.

Called ABX464, this treatment had obtained the status of national research priority.

In May 2020, he received the green light from the French regulatory authorities (ANSM) to be tested against Covid-19, during a clinical trial called "miR-AGE" which included 1,034 patients.